Diversified healthcare bellwether Johnson & Johnson (NYSE:JNJ) reported decent third quarter sales trends on October 18, though profits fell. Despite continued tepid near-term results, J&J stands out for its product and sales diversification. And though upside potential remains questionable, the stock has protected investors on the downside. Year-to-date, it is up 5% while the overall market is down about 5%.

Investopedia Markets: Explore the best one-stop source for financial news, quotes and insights.

Third Quarter Recap
Sales advanced 6.8% to $16 billion, though operational growth was quite modest at 2.6%. Positive currency fluctuations accounted for 4.2% of the total quarterly growth. International sales improved a healthy 8.3% organically, while positive foreign exchange movements boosted reported overseas growth to 16.4% and 57% of total sales. Domestic trends were more challenging, as sales fell 3.7% to account for 43% of total sales.

By product area, reported medical device sales rose 1.7% and represented close to 40% of the total top line. Pharmaceutical sales represented the next-largest category at more than 37% of total sales. This category saw sales jump 8.9%, as international sales rose 27.5% and offset a 6.1% domestic decline, due primarily to generic competition of bacterial-treatment drug Levaquin. Consumer sales made up the remaining 23% of sales and grew a healthy 4.9%, despite a number of remaining product recalls and "ongoing efforts to enhance quality and manufacturing systems".

A double-digit increase in selling costs and operating selling, marketing and administrative expenses sent operating income down 2.6% to $4.1 billion. Income tax expense also jumped in the double digits and sent net income down 6.3% to $3.2 billion, or $1.15 diluted earnings per share (diluted EPS). However, this still resulted in an impressive net profit margin of 20%. (To learn more about investment quality, check out: Find Investment Quality In The Income Statement.)

J&J expects to report full-year earnings between $4.95 and $5 diluted EPS, excluding the impact of special items. Analysts currently project full-year sales growth of 6% and total sales of more than $65 billion.

Bottom Line
J&J trades at a reasonable forward P/E of 13 and sports an above-average dividend yield of 3.5%. However, growth in recent years has been an issue. Over the past three years, sales have barely budged, though earnings are up close to 10% annually on average. The five-year figures show stronger annual sales growth of 4%, but weaker profit growth of below 7%.

Compared to pure-play pharmaceutical rivals including Pfizer (NYSE:PFE) and Merck (NYSE:MRK), J&J has a clearer growth profile, though this is due in good part to its non-pharma divisions. The consumer unit should eventually see a sales rebound from a surprising number of product recalls and manufacturing deficiencies. The medical device unit also continues to benefit from strong demand and acquisitions, though pure-play rival Medtronic (NYSE:MDT) currently looks like a better bet at less than 10 times forward earnings. But J&J still represents one of the best ways to play a broad array of healthcare product categories across the globe. Abbott Laboratories (NYSE:ABT) is an equally compelling play and trades at a forward P/E of just over 11.

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Stock Analysis

    Allstate: How Being Boring Earns it Billions (ALL)

    A summary of what Allstate Insurance sells and whom it sells it to including recent mergers and acquisitions that have helped boost its bottom line.
  2. Options & Futures

    Cyclical Versus Non-Cyclical Stocks

    Investing during an economic downturn simply means changing your focus. Discover the benefits of defensive stocks.
  3. Investing Basics

    How to Deduct Your Stock Losses

    Held onto a stock for too long? Selling at a loss is never ideal, but it is possible to minimize the damage. Here's how.
  4. Economics

    Is Wall Street Living in Denial?

    Will remaining calm and staying long present significant risks to your investment health?
  5. Stock Analysis

    When Will Dick's Sporting Goods Bounce Back? (DKS)

    Is DKS a bargain here?
  6. Investing News

    How AT&T Evolved into a Mobile Phone Giant

    A third of Americans use an AT&T mobile phone. How did it evolve from a state-sponsored monopoly, though antitrust and a technological revolution?
  7. Stock Analysis

    Home Depot: Can its Shares Continue Climbing?

    Home Depot has outperformed the market by a wide margin in the last 12 months. Is this sustainable?
  8. Stock Analysis

    Yelp: Can it Regain its Losses in 2016? (YELP)

    Yelp investors have had reason to be happy recently. Will the good spirits last?
  9. Stock Analysis

    Is Walmart's Rally Sustainable? (WMT)

    Walmart is enjoying a short-term rally. Is it sustainable? Is Amazon still a better bet?
  10. Stock Analysis

    GoPro's Stock: Can it Fall Much Further? (GPRO)

    As a company that primarily sells discretionary products, GoPro and its potential falls right in line with consumer trends. Is that good or bad?
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center